The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 39, Issue 3, 1997, Pages 673-680

  Whittington, Richard ^a,b   Malkowicz, S Bruce ^a   Machtay, Mitchell ^a   Van Arsdalen, Keith ^a   Barnes, Margaret M ^a   Broderick, Gregory A ^a   Wein, Alan J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hormonal therapy; Metastatic adenopathy; Prostate cancer; Radiation therapy

Indexed keywords

DIETHYLSTILBESTROL; GONADORELIN;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS; MULTIMODALITY CANCER THERAPY; ORCHIECTOMY; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE;

ADENOCARCINOMA; AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COMBINED MODALITY THERAPY; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORCHIECTOMY; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 0030929179     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(97)00369-6     Document Type: Article

References (21)

1. Anscher, M. S.; Prosnitz, L. R. Prognostic significance of extent of nodal involvement in stage D1 prostate cancer treated with radiotherapy. Urology 39:39-43; 1992.
2. Cheng, C. W. S.; Bergstralh, E. J.; Zinke, H. Stage D1 prostate cancer: A nonrandomized comparison of conservative treatment options versus radical prostatectomy. Cancer 71:996-1004; 1993.
3. Chodak, G. W.; Thisted, R. A.; Gerber, G. S.; Johansson, J.-E.; Adolfsson, J.; Jones, G. W.; Chisholm, G. D.; Moskovitz, B.; Livne, P. M.; Warner, J. Results of conservative management of clinically localized prostate cancer. N. Engl. J. Med. 330:242-248; 1994.
4. Fleming C.; Wasson, J. H.; Albertsen, P. C.; Barry, M. J.; Wennberg, J. E. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 269: 2650-2658; 1993.
5. Garnick, M. B. The dilemmas of prostate cancer. Sci. Am. 270:72-81; 1994.
6. Gervasi, L. A.; Mata, J.; Easley, J. D.; Wilbanks, J. H.; Seale-Hawkins, C.; Carlton, C. E.; Scardino, P. T. Prognostic significance of lymph node metastases in prostate cancer J. Urol. 142:332-346; 1989.
7. Hanks, G. E. The challenge of treating node positive prostate cancer: An approach to resolving the questions. Cancer 71: 1014-1018;, 1993.
8. Kramer, S. A.; Cline, W. A.; Farnham, R.; Carson, C. C.; Cox, E. B.; Hinshaw, W.; Paulson, D. F. Prognosis of patients with stage D1 prostatic adenocarcinoma. J. Urol. 125:817-819; 1981.
9. Lawton, C. A.; Coz, J. D.; Glisch, C.; Murray, K. J.; Byhardt, R. W.; Wilson, J. F. Is long term survival possible with external beam irradiation for stage D1 adenocarcinoma of the prostate? Cancer 69:2671-2766; 1992.
10. Leibel, S. A.; Fuks, Z.; Zelefsky, M. J.; Whitmore, W. F. The effect of local and regional treatment on the metastatic outcome in prostate carcinoma with pelvic lymph node involvement. Int. J. Radiat Oncol. Biol. Phys. 28:7-16; 1994.
11. Paulson, D. F.; Hodge, G. B.; Hinshaw, W. Radiation therapy versus delayed androgen deprivation for stage C carcinoma of the prostate. J. Urol. 131:901-902; 1984.
12. Pilepich, M. F.; Al-Sarraf, M.; Roach, M., III; Doggett, R. L.; Sause, W.; Lawton, C. A.; Abrams, R. A.; Rotman, M.; Rubin, P.; Shipley, W. U.; Cox, J. D. A phase III trial of androgen suppression before and during radiation therapy for locally advanced prostate carcinoma: Preliminary report of RTOG 8610. Proc. ASCO 12:703; 1993.
13. Pistenmaa, D. A.; Bagshaw, M. A.; Freiha, F. S. Extended field radiation therapy for prostatic adenocarcinoma: Status report of a limited prospective trial. In: Johnson, D. E.; Samuels, M. L., eds. Cancer of the genitourinary tract New York Raven Press; 1979:229-247.
14. Sands, M. E.; Pollack, A.; Zagars, G. K. Influence of radio therapy on node positive prostate cancer treated with androgen ablation. Int. J. Radiat. Oncol. Biol. Phys. 31:13-20; 1995.
15. Steel, G. G.; Peckham, M. J. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int. J. Radiat. Oncol. Biol. Phys. 5:85-91; 1979.
16. Steinberg, G. D.; Epstein, J. I.; Piantadosi, S.; Walsh, P. C. Management of D1 adenocarcinoma of the prostate: The Johns Hopkins experience 1974-1987. J. Urol. 144:1425-1432; 1990.
17. Taylor, C. D.; Trump, D. L.; Citrin, D. L.; Elson, P.; Messing, E.; Cummings, K.; Jordan, V. C. Survival (S) impact of continued testicular androgen suppression in refractory prostate cancer. Pro. ASCO 8:502; 1989.
18. Van Aubel, O. G. J. M.; Hoekstra, W. J.; Schroder, F. H. Early orchiectomy for patients with stage D1 prostatic carcinoma. J. Urol. 134:292-294; 1985.
19. Whittington R.; Malkowicz, S. B.; Barnes, M. M.; Broderick, G. A.; Van Arsdalen, K.; Dougherty, M. J.; Wein, A. J. Combined hormonal and radiation therapy for lymph node-positive prostate cancer. Urology 46:213-219; 1994.
20. Zagars, G. K.; Sands, M. E.; Pollack, A.; Von Eschenback, A.C. Early androgen ablation for stage D1 (N1 to N3, M0) prostate cancer: Prognostic variables and outcome. J. Urol. 151:1330-1333; 1994.
21. Zinke, H.; Bergstrath, E. J.; Larson-Keller, J. J.; Farrow, G. M.; Myers, R. P.; Lieber, M. M.; Barrett, G. M.; Rife, C. C.; Gonchoroff, N. J. Stage D1 prostate cancer treated by radical prostatectomy and adjuvant hormonal treatment. Cancer 70:311-323; 1992.